Hormone receptor-positive (HR+) breast cancer subtypes (luminal A and B) represent approximately 60–75% of all breast cancers and respond well to endocrine therapy (ET), in both adjuvant and metastatic setting. This evidence concerns the gene NR4A1 and breast carcinoma.